Paper42985589PubMed
Exploration of the Pathogenesis and Treatment of Heart Failure.
Wen B and 2 others. Rev Cardiovasc Med, 2026.
Cite this record
ConductScience Library. Exploration of the Pathogenesis and Treatment of Heart Failure. Papers, record 42985589. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42985589
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Exploration of the Pathogenesis and Treatment of Heart Failure.
- Journal
- Rev Cardiovasc Med
- Year
- 2026
- Publication types
- Journal Article, Review
- Revised in PubMed
- 2026-11-06
Source PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References134
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 40521614 | The crosstalk between immune activation and metabolism in heart failure. A scientific statement of the Heart Failure Association of the ESC. | Eur J Heart Fail | 2025 | https://conductscience.org/library/papers/40521614 | PubMed |
| 2 | 41462938 | Cellular and Molecular Mechanisms of Heart Failure and Sudden Cardiac Death in Hypertrophic Cardiomyopathy and Methods Used for Their Pathogenetic Correction. | Biomedicines | 2025 | https://conductscience.org/library/papers/41462938 | PubMed |
| 3 | 37623365 | Autophagy in Heart Failure: Insights into Mechanisms and Therapeutic Implications. | J Cardiovasc Dev Dis | 2023 | https://conductscience.org/library/papers/37623365 | PubMed |
| 4 | 40931092 | Heart failure-specific cardiac fibroblasts contribute to cardiac dysfunction via the MYC-CXCL1-CXCR2 axis. | Nat Cardiovasc Res | 2025 | https://conductscience.org/library/papers/40931092 | PubMed |
| 5 | 40318256 | Valine acts as an early biomarker and exacerbates pathological cardiac hypertrophy by impairing mitochondrial quality control. | Atherosclerosis | 2025 | https://conductscience.org/library/papers/40318256 | PubMed |
| 6 | 39225278 | Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. | N Engl J Med | 2024 | https://conductscience.org/library/papers/39225278 | PubMed |
| 7 | 40892608 | Pharmacologic Treatment of Heart Failure With Reduced Ejection Fraction: An Updated Systematic Review and Network Meta-Analysis. | J Am Coll Cardiol | 2025 | https://conductscience.org/library/papers/40892608 | PubMed |
| 8 | 34922348 | The 'Ten Commandments' of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. | Eur Heart J | 2022 | https://conductscience.org/library/papers/34922348 | PubMed |
| 9 | 40022104 | Complex regulation of cardiac fibrosis: insights from immune cells and signaling pathways. | J Transl Med | 2025 | https://conductscience.org/library/papers/40022104 | PubMed |
| 10 | 38616546 | Ca2+/calmodulin-dependent kinase IIδC-induced chronic heart failure does not depend on sarcoplasmic reticulum Ca2+ leak. | ESC Heart Fail | 2024 | https://conductscience.org/library/papers/38616546 | PubMed |
| 11 | 33983836 | Cardiac Energy Metabolism in Heart Failure. | Circ Res | 2021 | https://conductscience.org/library/papers/33983836 | PubMed |
| 12 | 40195182 | MLKL-Mediated Necroptosis Predominantly Contributes to Immune-Associated Myocardial Damage. | Inflammation | 2025 | https://conductscience.org/library/papers/40195182 | PubMed |
| 13 | 39600110 | Cardiac remodelling in the era of the recommended four pillars heart failure medical therapy. | ESC Heart Fail | 2025 | https://conductscience.org/library/papers/39600110 | PubMed |
| 14 | 40461989 | Emerging role of the cGAS-STING pathway in cardiovascular diseases: biologic function, mechanisms and targeted therapy. | Mol Med | 2025 | https://conductscience.org/library/papers/40461989 | PubMed |
| 15 | 34895860 | A Systematic Review and Network Meta-Analysis of Pharmacological Treatment of Heart Failure With Reduced Ejection Fraction. | JACC Heart Fail | 2022 | https://conductscience.org/library/papers/34895860 | PubMed |
| 16 | 40394351 | METTL3-mediated m⁶A methylation in cardiac diseases: pathogenic roles and therapeutic potential. | Cell Biol Toxicol | 2025 | https://conductscience.org/library/papers/40394351 | PubMed |
| 17 | 32694759 | Mitochondrial Ca2+ regulation in the etiology of heart failure: physiological and pathophysiological implications. | Acta Pharmacol Sin | 2020 | https://conductscience.org/library/papers/32694759 | PubMed |
| 18 | 39297138 | Reassessing the Mechanisms of PLN-R14del Cardiomyopathy: From Calcium Dysregulation to S/ER Malformation. | JACC Basic Transl Sci | 2024 | https://conductscience.org/library/papers/39297138 | PubMed |
| 19 | 39446238 | Leukocyte infiltration and cross-talk with cardiomyocytes exploit intracellular stress pathways in dilated cardiomyopathy of idiopathic origin. | Mol Biol Rep | 2024 | https://conductscience.org/library/papers/39446238 | PubMed |
| 20 | 41169425 | Autoimmune inflammation as a key risk factor for heart failure with preserved ejection fraction: the different types of inflammation driving to HFpEF. | Front Med (Lausanne) | 2025 | https://conductscience.org/library/papers/41169425 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42985589
GET https://conductscience.org/api/papers/v1/42985589/references?page=2